Novavax (NASDAQ:NVAX) has climbed 3.08% in the past week and advanced 27.67% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 4.32% and the outperformance has advanced to 26.51% for the last 4 weeks period.
Novavax (NASDAQ:NVAX): The stock opened at $6.81 on Friday but the bulls could not build on the opening and the stock topped out at $6.89 for the day. The stock traded down to $6.66 during the day, due to lack of any buying support eventually closed down at $6.69 with a loss of -1.18% for the day. The stock had closed at $6.77 on the previous day. The total traded volume was 9,458,950 shares.
The company shares have dropped -28.68% from its 1 Year high price. On Aug 11, 2015, the shares registered one year high at $15.01 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $5.59 and the 200 Day Moving Average price is recorded at $5.93.
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Novavax Inc, Evans Gary C had sold 18,998 shares worth of $123,487 in a transaction dated June 6, 2016. In this transaction, 18,998 shares were sold at $6.5 per share.
Many analysts have stated their opinion on the company shares. Chardan Capital initiates coverage on Novavax (NASDAQ:NVAX). Chardan Capital has a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $5.75 per share. The rating by the firm was issued on April 4, 2016. Currently the company Insiders own 3.5% of Novavax shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.98% . Institutional Investors own 81.99% of Novavax shares. During last six month period, the net percent change held by insiders has seen a change of -16.33%.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).